Skip to main content
Breadcrumb

Measurable residual disease in acute myeloid leukemia

Research group
Active research
Project owner
Institute of Biomedicine

Short description

Our research group is focused on improving diagnostics in acute myeloid leukemia (AML). Specifically, we develop and evaluate tools for analysis of small amounts of leukemic cells, measurable residual disease (MRD). These tools can help in treatment decisions and/or be used for monitoring for early detection of relapse. We readily transfer our results to clinical use at the Department of Clinical Chemistry and Center for Medical Genomics. While aiding the clinic with these tools, we also provide increased knowledge about the genetics and disease course of AML.

Acute myeloid leukemia (AML) is the most common form of acute leukemia. Unfortunately, the prognosis is poor, mostly due to high frequency of relapses using the current treatment strategies. Over the last years, it has become increasingly evident that the response to AML treatment, measurable residual disease (MRD), is a very strong prognostic factor. However, problems with standardization and applicability in individual patients hamper clinical usage of MRD analyses.

Our research focuses on improvement and usage of analyses of measurable residual disease (MRD). We have recently developed a novel analysis using next generation sequencing for MRD in AML based on the presence of leukemia-specific mutations. We currently evaluate the clinical usability of this new technique called deep sequencing. We are also working with evaluation and improvement of the more established methods for MRD analysis; flow cytometry and RT-qPCR.

Our work is closely linked to the hematology diagnostics departments at Sahlgrenska University Hospital. The overall aim of our research is to improve the basis for treatment decisions for children and adults with acute leukemia. Due to an in increased treatment arsenal, we also work on early detection relapse in AML. We collaborate closely with clinical hematologists and pediatric oncologists and take active part in the Nordic Organization for Pediatric Hematology and Oncology and the Swedish AML group. For technical implementation of new techniques, we work closely with groups at Chalmers University of Technology.  Together with our neighboring groups Lars Palmqvist, Julia Asp and Meena Kanduri, we form the Leukemia Research Laboratory, aiming for a fruitful hematological research environment and continuous translation of research results into clinical diagnostics. 

Linda Fogelstrand
Group members

Linda Fogelstrand

Anastasia Soboli

Anna Rehammar

Azadeh Anbarlou

Borhan Saeed

Erik Delsing Malmberg

Giti Shah Barkhordar

Gustav Orrsjö

Lene Karlsson

Sofie Johansson Alm